Abstract
Zixuan Bai, Jiewen Wang, Haibin Yuan, Yuanhang Feng, Xiangtong Cao, Xiangan Cao, Guangbo Kang, Ario de Marco
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1016/s0140-6736(12)60026-9
10.1016/s0140-6736(12)60026-9
10.1016/s0140-6736(12)60150-0
10.1016/s0140-6736(12)60150-0
10.1016/s0140-6736(17)30570-6
10.1016/s0140-6736(17)30570-6
Aminosalicylates for induction of remission or response in Crohn's disease
2016
Infliximab, azathioprine, or combination therapy for Crohn's disease
10.1056/nejmoa0904492 · 2010
10.1016/s0140-6736(02)08512-4
10.1016/s0140-6736(02)08512-4
Adalimumab induces deep remission in patients with Crohn's disease
10.1016/j.cgh.2013.06.019 · 2014
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial
10.1053/j.gastro.2007.03.024 · 2007
Ustekinumab as induction and maintenance therapy for Crohn's disease
10.1056/nejmoa1602773 · 2016
Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naive to or who have failed tumor necrosis factor antagonist therapy
10.1097/mib.0000000000000979 · 2017
10.1038/nrgastro.2013.253
10.1038/nrgastro.2013.253
Management of inflammatory bowel disease in poor responders to infliximab
2014
10.1136/gutjnl-2017-315671
10.1136/gutjnl-2017-315671
10.1016/s0140-6736(17)32448-0
10.1016/s0140-6736(17)32448-0
Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study
10.1053/j.gastro.2017.03.049 · 2017
Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
10.2147/jir.s165330 · 2018
Fine-tuning bispecific therapeutics
2020
Research progress and applications of multivalent, multispecific and modified nanobodies for disease treatment
10.3389/fimmu.2021.838082 · 2021
10.1038/363446a0
10.1038/363446a0
Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target
10.1517/14712598.2013.800478 · 2013
10.1016/j.jaad.2019.03.056
10.1016/j.jaad.2019.03.056
10.1007/s10555-005-6193-1
10.1007/s10555-005-6193-1
10.1126/science.1241145
10.1126/science.1241145
A consensus protocol for the in silico optimisation of antibody fragments
10.1039/c9cc06182g · 2019
10.1038/nbt1336
10.1038/nbt1336
Assisted design of antibody and protein therapeutics (ADAPT
10.1371/journal.pone.0181490 · 2017
Homology modeling-based in silico affinity maturation improves the affinity of a nanobody
10.3390/ijms20174187 · 2019
In vitro affinity maturation to improve the efficacy of a hypoxia-inducible factor 1alpha single-domain intrabody
10.1016/j.bbrc.2020.06.097 · 2020
VHH212 nanobody targeting the hypoxia-inducible factor 1alpha suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo
10.20892/j.issn.2095-3941.2020.0568 · 2021
Neutralization of human interleukin 23 by multivalent nanobodies explained by the structure of cytokine-nanobody complex
10.3389/fimmu.2017.00884 · 2017
Bivalent Llama single-domain antibody fragments against tumor necrosis factor have picomolar potencies due to intramolecular interactions
10.3389/fimmu.2017.00867 · 2017
10.1093/nar/gki387
10.1093/nar/gki387
mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signatures
10.1093/nar/gkw458 · 2016
10.1002/jcc.25522
10.1002/jcc.25522
Designing and constructing a phage display synthesized single domain antibodies library based on camel VHHs frame for screening and identifying humanized TNF-alpha-specific nanobody
2021
A highly sensitive detection system based on proximity-dependent hybridization with computer-aided affinity maturation of a scFv antibody
10.1038/s41598-018-22111-4 · 2018
10.1371/journal.pcbi.1006980
10.1371/journal.pcbi.1006980
Computer-guided library generation applied to the optimization of single-domain antibodies
10.1093/protein/gzaa006 · 2019
Nanobody affinity improvement: Directed evolution of the anti-ochratoxin A single domain antibody
10.1016/j.ijbiomac.2020.02.180 · 2020
Repertoire analysis of antibody CDR-H3 loops suggests affinity maturation does not typically result in rigidification
10.3389/fimmu.2018.00413 · 2018
THE weighted histogram analysis method for free-energy calculations on biomolecules. I. The method
10.1002/jcc.540130812 · doi-reference
10.1021/jp9110794
10.1021/jp9110794 · doi-reference
10.1016/j.jmb.2015.09.014
10.1016/j.jmb.2015.09.014 · doi-reference
10.1038/s41586-021-03819-2
10.1038/s41586-021-03819-2 · doi-reference
Effect of humanizing mutations on the stability of the llama single-domain variable region
10.3390/biom11020163 · doi-reference
10.1002/pro.3330
10.1002/pro.3330 · doi-reference
Application of assisted design of antibody and protein therapeutics (ADAPT) improves efficacy of a Clostridium difficile toxin A single-domain antibody
10.1038/s41598-018-20599-4 · doi-reference
InterProSurf: a web server for predicting interacting sites on protein surfaces
10.1093/bioinformatics/btm474 · doi-reference
Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G
10.1016/0019-2791(71)90454-x · doi-reference
10.3109/08820139709088539
10.3109/08820139709088539 · doi-reference
A global benchmark study using affinity-based biosensors
10.1016/j.ab.2008.11.021 · doi-reference
10.1016/j.addr.2012.09.039
10.1016/j.addr.2012.09.039 · doi-reference
Design and optimization of a linker for fusion protein construction
10.1016/j.pnsc.2008.12.007 · doi-reference
10.1039/c8cs00523k
10.1039/c8cs00523k · doi-reference
10.1038/srep45259
10.1038/srep45259 · doi-reference